GlycoMimetics Stock (NASDAQ:GLYC)


ForecastOwnershipFinancialsChart

Previous Close

$16.15

52W Range

$0.15 - $63.00

50D Avg

$22.49

200D Avg

$24.90

Market Cap

$1.01B

Avg Vol (3M)

$19.73K

Beta

1.60

Div Yield

-

GLYC Company Profile


GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jan 10, 2014

Website

GLYC Performance


GLYC Financial Summary


Dec 24Dec 23Dec 22
Revenue-$10.00K$74.92K
Operating Income$-40.04B$-39.28M$-47.40M
Net Income-$-36.90M$-93.33M
EBITDA$-40.04B$-39.12M$-47.20M
Basic EPS$-0.59$-0.58$-1.78
Diluted EPS$-0.59$-0.58$-1.78

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 24May 06, 24 | 12:00 AM
Q4 23Mar 27, 24 | 8:30 AM
Q3 23Nov 03, 23 | 8:30 AM

Peer Comparison


TickerCompany
SLNSilence Therapeutics plc
CDTXCidara Therapeutics, Inc.
CTMXCytomX Therapeutics, Inc.
MGNXMacroGenics, Inc.
GLMDGalmed Pharmaceuticals Ltd.
APLTApplied Therapeutics, Inc.